#USA #Los Angeles #Schall Law Firm #SEC Fraud #Unicycive Therapeutics

Investors Encouraged to Join Unicycive Therapeutics Class Action

In the wake of recent developments, investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) face a crucial opportunity to engage in a class action lawsuit initiated by the Schall Law Firm. This national legal firm focuses on shareholder rights and is urging affected investors who purchased Unicycive securities between March 29, 2024, and June 27, 2025, to take action before the upcoming deadline on October 14, 2025.

Allegations Against Unicycive

The impetus for this legal action arises from claims that Unicycive significantly misled the market regarding its compliance with FDA manufacturing requirements. The company allegedly overstated its potential to gain FDA approval for OLC, a treatment targeting hyperphosphatemia in chronic kidney disease (CKD) patients undergoing dialysis. Such statements have been deemed materially misleading, significantly impacting the value of shares held by investors once the truth came to light.

The Role of the Schall Law Firm

The Schall Law Firm is prepared to represent investors in this class action suit, focusing on violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and the corresponding Rule 10b-5 enforced by the U.S. Securities and Exchange Commission (SEC). As the case stands, formal class certification has yet to be achieved, meaning that affected investors have not yet secured legal representation unless they actively join the lawsuit.

Why Should Investors Act?

Given the allegations, the Schall Law Firm emphasizes the potential for affected shareholders to recover their losses. By participating, investors may assert their rights and collectively hold Unicycive accountable for the alleged deceptive practices. The firm highlights that sharing detailed accounts of losses could strengthen the case and bolster investors' positions.

Next Steps for Investors

Those who believe they have suffered financial losses should consider contacting Brian Schall at the Schall Law Firm for a complimentary discussion regarding their rights. Interested parties can contact the firm via phone or through their website. As the legal landscape regarding shareholder rights continues to evolve, timely action could be key to recovery for those impacted.

Conclusion

This class action lawsuit represents a significant moment for investors who feel wronged by Unicycive Therapeutics. As the deadline approaches, it remains crucial for shareholders to take informed and decisive steps to engage in the legal process. Together, investors may reclaim their losses and address the alleged misconduct of Unicycive.

For any affected investors, visiting the Schall Law Firm website or making direct contact might provide the necessary guidance and support needed to navigate this complex legal situation. History has shown that collective legal action can often yield favorable results for those seeking justice in the financial realm.